Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for irritable bowel syndrome
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in IrritableBowelSyndrome With Constipation Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritablebowelsyndrome with constipation (IBS-C).This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients (...) to placebo or 290 μ g oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration ’ s (FDA ’ s) primary end point for IBS-C (responder: improvement of ≥ 30 % in average daily worst abdominal pain score and increase by ≥ 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50 % of weeks assessed) and three other primary end points, based on improvements
Linaclotide for IrritableBowelSyndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritablebowelsyndrome with constipation (IBS-C) over 26 weeks.This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients (...) to placebo or 290 μg of oral linaclotide once daily for a 26-week treatment period. The primary and the secondary efficacy assessments were evaluated over the first 12 weeks of treatment. Primary end points included the Food and Drug Administration's (FDA's) end point for IBS-C (responder: a patient who reported (i) improvement of ≥ 30 % from baseline in average daily worst abdominal pain score and (ii) increase of ≥ 1 complete spontaneous bowel movement (CSBM) from baseline, both in the same week
Mindfulness meditation for women with irritablebowelsyndrome--evidence of benefit from a randomised controlled trial. 22531145 2012 09 24 2012 07 06 1468-9618 15 3 2012 Jul Evidence-based nursing Evid Based Nurs Mindfulness meditation for women with irritablebowelsyndrome--evidence of benefit from a randomised controlled trial. 80-1 10.1136/ebnurs-2012-100488 Kearney David J DJ Department of Medicine, VA Puget Sound Health Care System, Seattle, Washington 98108, USA. kearney
obtaining breath samples before and at timed intervals after ingesting a carbohydrate substrate and analyzing these samples for hydrogen (H2) content. Intestinal bacteria ferment the carbohydrate, producing the only source of bodily H2, which is expelled in the breath. The pattern and degree of expelled H2 may indicate the presence of particular gastrointestinal (GI) disorders. Irritablebowelsyndrome (IBS) is a chronic GIdisorder that is diagnosed only by symptoms but shares symptoms with other GI (...) conditions. In patients with IBS, the HBT is performed to identify GIconditions that may be responsible for symptoms and may be treatable, potentially providing symptom relief. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breath Tests; Hydrogen; IrritableBowelSyndromes Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S
in the United States. Gastroenterology. 2002;122(5):1500-1511. 3. Galatola G, Grosso M, Barlotta A, et al. [Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinaldiseases]. Minerva gastroenterol dietol. 1991;37(3):169-175. 4. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritablebowelsyndrome. Am J Gastroenterol. 2000;95(12):3503-3506. 5. Pimentel M, Chow EJ, Lin HC (...) and gastroenterologists. The workup is often extensive and rules out many etiologies. After discovering no metabolic, inflammatory, or anatomic pathology, physicians use the Rome III criteria to diagnose irritablebowelsyndrome (IBS). IBS is a functional boweldisorder that is diagnosed by symptoms of recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months and associated with 2 or more of the following: 1) improvement with defecation, 2) onset associated with a change in frequency
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritablebowelsyndrome with constipation Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-concept study for the treatment of patients with irritablebowelsyndrome (IBS) with constipation (IBS-C). We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C.We performed a randomized, double-blind (...) , multicenter, placebo-controlled study of 420 patients with IBS-C given oral linaclotide at doses of 75, 150, 300, or 600 μg or placebo once daily for 12 weeks. End points included change from baseline in daily bowel habits, daily abdominal symptoms, and weekly global assessments, in addition to responder criteria.All doses of linaclotide significantly improved bowel habits, including frequency of spontaneous bowel movements and complete spontaneous bowel movements (primary end point), severity
Rifaximin therapy for patients with irritablebowelsyndrome without constipation. Evidence suggests that gut flora may play an important role in the pathophysiology of the irritablebowelsyndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS.In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg (...) a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study.Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two
Chenodeoxycholate in females with irritablebowelsyndrome-constipation: a pharmacodynamic and pharmacogenetic analysis Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritablebowelsyndrome (IBS-C).In a double-blind placebo-controlled study, 36 female patients with IBS-C were randomized to treatment with delayed-release oral formulations (...) of placebo, 500 mg CDC, or 1000 mg CDC for 4 days. We assessed gastrointestinal and colonic transit, stool characteristics, and associations of transit with fasting serum 7αC4 (surrogate of bile acid synthesis) and FGF19 (negative regulator of bile acid synthesis) levels. Candidate genetic polymorphisms involved in regulation of bile acid synthesis were analyzed in the 36 patients with IBS-C and 57 healthy volunteers to assess genetic influence on effects of CDC on transit.Overall colonic transit
A randomized, double-blind, placebo-controlled trial of St John`s wort for treating irritablebowelsyndrome St John's wort (SJW) is known to effectively treat patients with mild-to-moderate depression. Antidepressants are frequently used to treat irritablebowelsyndrome (IBS). To date, no study that examines the efficacy of SJW in IBS has been carried out. The aim of this study was to evaluate the efficacy of SJW in IBS after 12 weeks.In this randomized, double-blind, placebo-controlled trial (...) , 70 participants with an established diagnosis of IBS were randomized and assigned by concealed allocation to either SJW or placebo. Both treatment arms were balanced on symptom subtype. The primary end point was self-reported overall bowel symptom score (BSS) at 12 weeks. Secondary end points were individual BSS for diarrhea (D-BSS), constipation (C-BSS), pain or discomfort, and bloating; adequate relief (AR) of IBS on at least 50% of the last 4 weeks of therapy; and IBS quality-of-life score
of medical costs was the highest at 60.0%, followed by transportation costs at 15.4% and productivity loss costs at 24.8%. If other medical costs incurred by patients, such as over-the-counter drug costs and health food costs, are added to the aforementioned costs, the total amount is estimated to be 773.8 billion won. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cost of Illness; Humans; IrritableBowelSyndrome; Korea Language Published Korean Country of organisation South (...) [Burden of irritablebowelsyndrome in Korea] [Burden of irritablebowelsyndrome in Korea] [Burden of irritablebowelsyndrome in Korea] Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park HJ, Lee PL, Lee JS, Lee KJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park
The place of antibiotics in management of irritablebowelsyndrome: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Comprehensive self-management for irritablebowelsyndrome: randomized trial of in-person vs. combined in-person and telephone sessions Psychological and behavioral therapies are being increasingly used for symptom management in patients with irritablebowelsyndrome (IBS). The aims of this study were to compare two delivery modes for a comprehensive self-management (CSM) intervention, primarily by telephone vs. entirely in person, and to compare each with usual care (UC).Adults with IBS were (...) recruited through community advertisement. Subjects (N=188) were randomly assigned to three groups: one in which all nine weekly CSM sessions were delivered in person, one in which six of the nine sessions were conducted over telephone, and one in which subjects received UC. Primary outcome measures were a gastrointestinal (GI) symptom score based on six symptoms from a daily diary and disease-specific quality of life (QOL). These and other outcomes were assessed at baseline and at 3, 6, and 12 months
Systematic review: self-management support interventions for irritablebowelsyndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Effect of mesalazine on mucosal immune biomarkers in irritablebowelsyndrome: a randomized controlled proof of concept study Intestinal immune infiltration contributes to symptoms in patients with irritablebowelsyndrome (IBS).To assesses the effect of mesalazine (mesalamine) on mucosal immune cells in patients with IBS, through a pilot study.A randomized, double-blind, placebo-controlled trial in 20 patients with IBS in tertiary care setting. Patients were randomized to receive placebo (...) ). Mesalazine significantly increased general well-being (P = 0.038), but had no significant effects on abdominal pain (P = 0.084), bloating (P = 0.177) or bowel habits. No serious drug-related adverse events were reported during the study.Mesalazine is an effective and safe approach to reduce mast cell infiltration and may improve general well-being in patients with IBS. These results support the hypothesis that immune mechanisms represent potential therapeutic targets in IBS.
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritablebowelsyndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritablebowelsyndrome: systematic review and meta-analysis | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Effect of fibre,... Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritablebowelsyndrome (...) a negative value. Notes Cite this as: BMJ 2009;338:b1881 Article tools Article alerts Please note: your email address is provided to the journal, which may use this information for marketing purposes. Log in or register: Username * Password * If you have registered for alerts, you should use your registered email address as your username Download this article to citation manager Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritablebowelsyndrome: systematic review and meta
Dietary interventions for recurrent abdominal pain (RAP) and irritablebowelsyndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. It is unclear whether the diagnosis includes children with different aetiologies for their pain. For the majority no organic cause for their pain can be found on physical examination or investigation. Although most children are likely managed (...) by reassurance and simple measures, a large range of interventions have been recommended.To determine the effectiveness of dietary interventions for recurrent abdominal pain in school-age children.The Cochrane Library (CENTRAL) 2006 (Issue 4), MEDLINE (1966 to Dec 2006), EMBASE (1980 to Dec 2006), CINAHL (1982 to Dec 2007), ERIC (1966 to Dec 2006), PsycINFO (1872 to Dec 2006), LILACS (1982 to Dec 2006), SIGLE (1980 to March 2005), and JICST (1985 to 06/2000) were searched . Where appropriate, search filters
Psychological treatments may be effective for managing irritablebowelsyndrome PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Psychological treatments may be effective for managing irritablebowelsyndrome Clinical question How effective are psychological interventions for the treatment of irritablebowelsyndrome (IBS)? Bottom line Psychological interventions (cognitive behavioural therapy (...) of irritablebowelsyndrome. Cochrane Reviews 2009, Issue 1. Article No: CD006442. DOI: 10.1002/14651858.CD006442.pub2. This review contains 25 studies involving 1858 participants. PEARLS 156, April 2009, written by Brian R McAvoy [References] 1. Drossman DA et al. Gastroenterology 1997;112:2120-2137 are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement
Systematic review: accuracy of symptom-based criteria for diagnosis of irritablebowelsyndrome in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
was adequate symptom relief during at least two weeks in the previous month, analysed after one, two, and three months of treatment to assess both short term and sustained effectiveness. Secondary end points included irritablebowelsyndrome symptom severity score, severity of abdominal pain, and irritablebowelsyndrome quality of life scale.The proportion of responders was significantly greater in the psyllium group than in the placebo group during the first month (57% v 35%; relative risk 1.60, 95 (...) Soluble or insoluble fibre in irritablebowelsyndrome in primary care? Randomised placebo controlled trial. To determine the effectiveness of increasing the dietary content of soluble fibre (psyllium) or insoluble fibre (bran) in patients with irritablebowel syndrome.Randomised controlled trial.General practice.275 patients aged 18-65 years with irritablebowelsyndrome.12 weeks of treatment with 10 g psyllium (n=85), 10 g bran (n=97), or 10 g placebo (rice flour) (n=93).The primary end point